New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer

Authors

  • Katrine R. Schønnemann Department of Oncology, Odense University Hospital, Odense, Denmark; Institute of Clinical Research, University of Southern Denmark, Denmark
  • Mette Yilmaz Department of Oncology, Aalborg Hospital, Aalborg, Denmark
  • Maria Andersen Department of Oncology, Aalborg Hospital, Aalborg, Denmark
  • Per Pfeiffer Department of Oncology, Odense University Hospital, Odense, Denmark; Institute of Clinical Research, University of Southern Denmark, Denmark

DOI:

https://doi.org/10.3109/0284186X.2010.509738

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2011-01-01

How to Cite

Schønnemann, K. R., Yilmaz, M., Andersen, M., & Pfeiffer, P. (2011). New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer. Acta Oncologica, 50(1), 151–152. https://doi.org/10.3109/0284186X.2010.509738

Issue

Vol. 50 No. 1 (2011): Acta Oncologica

Section

Articles